Cargando...
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
BACKGROUND: In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain...
Gardado en:
| Publicado en: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4901121/ https://ncbi.nlm.nih.gov/pubmed/27067724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0405-0 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|